HIV

SUPPORT project launches to equip the next generation of African experts to fight childhood HIV 

2024

A new collaborative project called SUPPORT has officially launched to train the next generation of researchers who will focus on preventing mortality among these children.

The SUPPORT initiative, funded by EDCTP3 will run for 54 months and aims to equip early and mid-career researchers with expertise in clinical care, laboratory science, social science, and data analysis. The program will target researchers in Mozambique, Uganda, Zambia, Zimbabwe, and Senegal due to the high disease burden of HIV in these regions.

Read More

SUPPORT project launches to equip the next generation of African experts to fight childhood HIV 

2024

A new collaborative initiative, SUPPORTSupporting the next generation of African experts on preventing mortality among children living with HIV through translational training, has officially launched. The project funded by EDCTP3 will last 54 months. Through SUPPORT, eight early and five mid-career research fellows from Sub-Saharan African will be recruited to do a 36-month PhD for the early researchers, and a 24-month post-doctoral stay for the mid-career researchers in Mozambique,

Read More

PentaTr@ining Oman 2024: Working together to tackle vertical transmission of HIV, syphilis, and hepatitis B in maternal and child health

2024

From 14 to 16 May, 2024, PentaTr@ining in collaboration with UNICEF, the World Health Organization (WHO) and with support from the International Organization for Migration (IOM), brought together over 50 paediatric healthcare providers and programme leads from across 11 Middle East and North Africa (MENA) region countries for an innovative bespoke capacity-building workshop on the topic of eliminating vertical transmission of HIV,

Read More

EARTH study reveals high mortality rates among infants with HIV despite early treatment 

2024

EPIICAL’s EARTH Study reveals challenges persist for infants in Africa with HIV despite early treatment

The EARTH study findings published in eClinical Medicine shed light on the ongoing struggle for infants with HIV in Africa. While early treatment with antiretroviral therapy (ART) is crucial, the  Early Anti-Retroviral Treatment in Children (EARTH) study  found a concerningly high mortality rate within the first three years of life, even among treated infants.

Read More

CARMA Global study hits recruitment target

2023

The CARMA Global study, part of the EPIICAL project, has successfully met its recruitment target and recruited 99 children and adolescents living with HIV from across the globe. The study includes children and adolescents who acquired HIV around the period of their birth and then started antiretroviral therapy (ART) at a young age to control the virus and prevent its progression.

The primary aim of CARMA Global is to investigate how the body responds to HIV and how the virus is stored and behaves in the body over time.

Read More

Simultaneous pharmacokinetic modeling of unbound and total darunavir with ritonavir in adolescents: a substudy of the SMILE trial

2023

Authors: Abdalla S, Compagnucci A, Riault Y, Chan KM, Bamford A, Nolan A, Ramos TJ, Constant V, Nguyen T, Zheng Y, Tréluyer J, Froelicher-Bournaud L, Neveux N, Saidi Y, Cressey RT, Hirt D on behalf of the SMILE study group

Published in: Antimicrobial Agents and Chemotherapy

Read More

The UNIVERSAL project’s potential impact on the health of children living with HIV, told by Dr Vivian Mumbiro

2023

In recent years, advancements in medical research have paved the way for an array of treatment options for children living with HIV. The efforts of scientists and researchers globally, have led to continuous refinement and improvement of existing regimens. Dr. Vivian Mumbiro, affectionately known as Dr V, a dedicated Medical Officer at the University of Zimbabwe Clinical Research Centre, shares insights into the evolving landscape of paediatric HIV treatment.

Read More

Advancements in paediatric HIV research: Insights from the EPIICAL general assembly meeting 

2023

In the quest to enhance our understanding of paediatric HIV and improve treatment outcomes, the EPIICAL project has worked tirelessly for the past eight years to gather and generate knowledge on HIV in children. Established with the ambitious goal of creating models to predict how children’s bodies respond to early antiretroviral therapy (ART) and treatment interruption, the EPIICAL project has also aimed to refine methods for understanding immune,

Read More

Prediction of C-reactive protein dynamics during meropenem treatment in neonates and infants

2023

Authors: Soeorg H, Padari H, Ilmoja M-L, Herodes K, Kipper K, Lutsar I, Metsvaht T, NeoMero Consortium

Published in: British Journal of Clinical Pharmacology

Read More

What explains the poor contraction of the viral load during paediatric HIV infection?

2023

Authors: Schröter J & De Boer R

Published in: Journal of Theoretical Biology 2023

Read More

Effect of dolutegravir on folate, vitamin B12 and mean corpuscular volume levels among children and adolescents with HIV: a sub-study of the ODYSSEY randomized controlled trial 

2023

Authors: Barlow-Mosha L.N., Ahimbisibwe G.M., Chappell E., Amuge P.M., Nanduudu A., Kaudha E., Amukele T., Balamusani D., Kafufu B., Nimwesiga A., Kataike H., Namwanje R., Kasangaki G., Mulindwa A., Muzorah, G.A., Bbuye D., Musiime V., Mujyambere E., Ssenyonga M., Mulima D., Kyambadde R.C., Namusanje J., Isabirye R., Nabalamba M., Nakirya B.M., Kityo C., Kekitiinwa A.R., Giaquinto, C., Copp A., Gibb, D.M., Ford, D., Musoke P., Turkova A

Published in: Journal of the International AIDS Society

Read More

Relative bioavailability of dolutegravir (DTG) and emtricitabine/tenofovir alafenamide fumarate (F/TAF) administered as paediatric tablet formulations in healthy volunteers 

2023

Authors: Bevers LAH., Kamphuis AEM., van der Wekken-Pas LC, Leisegang R, Lewis L, Burger DM, Colbers A

Presented at: International Workshop on Clinical Pharmacology of HIV, Hepatitis, and Other Antiviral Drugs 2023

Read More

D3 trial completes recruitment ahead of schedule!

2023

The D3 trial is excited to announce that it has successfully completed recruitment in the trial at an exceptional speed. D3 is looking to see if a new tablet, a combination of two anti-HIV medicines, dolutegravir (DTG) and lamivudine (3TC), is as good and effective in treating HIV in children and young people living with HIV in comparison to the current paediatric anti-HIV medicines available.

The trial recruited 370 children from South Africa,

Read More

The Smooth Away From Expected (SAFE) non-inferiority frontier: theory and implementation with an application to the D3 trial

2023

Authors: Quartagno, M, Chan, M, Turkova, A et al.

Published in: Trials

Read More

Sensitive HIV-1 DNA Pol Next-Generation Sequencing for the Characterisation of Archived Antiretroviral Drug Resistance

2023

Authors: Botha JC, Byott M, Spyer MJ, Grant PR, Gärtner K, Chen WX, Burton J, Bamford A, Waters LJ, Giaquinto C, et al.

Published in: Viruses

Read More

Gilead partners with CHAI and Penta to improve treatment and adherence rates among children with HIV in low and middle income countries

2023

FOSTER CITY, Calif.–(BUSINESS WIRE)– Gilead Sciences, Inc. (Nasdaq: GILD) is pleased to announce two public-private partnerships. The first will accelerate the development of an investigational dispersible pediatric formulation containing emtricitabine and tenofovir alafenamide (F/TAF). The second aims to develop investigational pediatric formulations of TAF and sofosbuvir (SOF) designed to eliminate bitterness.

For more than 30 years, Gilead has been a leading innovator in the field of HIV, driving advances in treatment,

Read More

Penta hosts workshops on long-acting injectable antiretrovirals for children and adolescents  

2023

Between the months of April and May 2023, Penta hosted advisory group meetings where young people between the ages of 15 and 19 from South Africa, Argentina, the United Kingdom and Thailand, were invited to share their experiences and knowledge of long-acting injectable antiretrovirals at local in-person consultation workshops. The young people all had recent experience in paediatric HIV care and joined in the discussions about the acceptability, challenges and solutions of adopting and using long-acting injectables for themselves and their peers and how this could support or impact their transition to adult care.

Read More

SMILE once-daily regimen non-inferior to triple ART regimen

2023

Findings from the Strategy for Maintenance of HIV suppression with integrase inhibitor + darunavir/ritonavir in children (PENTA-17) trial, simply known as SMILE, were published in eClinicalMedicine on 2 June 2023. SMILE is the first randomised trial to determine whether children living with HIV on ART with suppressed viral load could maintain the suppression on a once-daily regimen compared to the standard of care (SOC) which involves three ART drugs. 

Read More
1 2 3 6